- Title
- Sapanisertib and serabelisib (PIKTOR) with paclitaxel, and an insulin-suppressing diet (ISD) substudy, in patients with advanced/recurrent endometrial cancer (EC): GOG-3111
- Creators
- Brian Slomovitz - Mount Sinai Medical CenterDavid Starks - Avera Medical Group Gynecologic Oncology, Sioux Falls, SD, United StatesBradley Monk - Florida Cancer Specialists and Research Institute, West Palm Beach, FL, United StatesJoyce Barlin - Women's Cancer Care Associates, Albany, NY, United StatesRamez Eskander - Moores Cancer CenterWeiya Wysham - Compass OncologyDanubia Hester - Maryland Oncology HematologyChristine Lee - Texas Oncology, The Woodlands, TX, United StatesAdrianne Mallen - MN Oncology, Edina, MN, United StatesCharles Anderson - Williamette Valley Cancer Institute and Research Center, Eugene, OR, United StatesAmanda Jackson - University of CincinnatiMaria Rubinstein - Memorial Sloan Kettering Cancer CenterOliver Maddocks - Faeth Therapeutics, Cambridge, United KingdomEdwin Alvarez - University of California, San FranciscoMamta Choksi - Florida Cancer Specialists & Research Institute, Trinity, FL, United StatesSarah Crafton - Allegheny Health NetworkSamantha DiBenedetto - Virginia Cancer SpecialistsTina Niazi - Faeth Therapeutics, Cambridge, United KingdomDebbie Chirnomas - Faeth Therapeutics, Cambridge, United Kingdom
- Publication Details
- Gynecologic oncology, Vol.208, pp.S105-S105
- Publisher
- Elsevier Inc
- Identifiers
- 991006271510502656
- Academic Unit
- Obstetrics & Gynecology
- Language
- English
- Resource Type
- Journal article
Journal article
Sapanisertib and serabelisib (PIKTOR) with paclitaxel, and an insulin-suppressing diet (ISD) substudy, in patients with advanced/recurrent endometrial cancer (EC): GOG-3111
Gynecologic oncology, Vol.208, pp.S105-S105
05/2026
Metrics
1 Record Views